Hamadan brucellosis research center

Infectious Disease Research Center (Brucellosis Reseach Center)

 Famenin Brucellosis Cohort Study

Hamadan University of Medical Sciences, Infectious Disease Research Center(Brucellosis Research Center)

Dr Fatemeh Torkamanasadi

Principal Investigator:

Fariba Keramat(retired) *

Fatemeh Torkamanasadi **


Professor of Tropical and Infectious Diseases

Hamadan University of Medical Sciences

Director, Brucellosis Research Center


Assistant Professor of Infectious Disease

Infection Disease Research Center

Shahid Beheshti Medical Educational Center

Health Vice chancellor of Hamadan Universtiy of Medical Sciences


Approved the 617th meeting of the Research Council of the Vice Chancellor for Research and Technology of Hamadan University of Medical Sciences


session for Announcement and introduction of cohort study


Coordination meeting and profile review

Stage1: • To determination of brucellosis seroprevalence in Famenin populations. • To Identification and prioritization of risk factors. Stage2: • To determination the seroprevalence of brucellosis in the livestock population. • To identification of human and livestock species • To determine Antibiotic resistance. • To study the Prevalence of microbial contamination of dairy products. • To determine the pattern of disease transmission. • To Intervention to control, reduce, and prevent. Stage 3: • To evaluation of implementer intervention on brucellosis incidence.

Urban and rural population and livestock in Famenin city ,Hamadan province ,Iran

Two stage sampling (clusters were selected using systematic sampling) in Famenin city population for serologic investigation in 3161 persons were used. All cases of brucellosis will enroll in the study All brucellosis cases, infected livestock and dairy products in Famenin city will investigate

Autumn 2014

The data in this study will be collected in three phases: Phase 1: Research was conducted to determine the serological status of human contamination and to identify and prioritize risk factors, and to record all cases of brucellosis. phase 2: In patients: clinical symptoms, transmission pattern, complications and recurrence, diagnostic and treatment methods, drug resistance will investigate. Investigations will be carried out to determine the serological status of livestock contamination. Educational interventions and vaccination of livestock will be done. Phase 3: Monitoring and intervention studies

Monitoring the clinical signs and seroprevalence of brucellosis in humans and livestock populations studied in Famenin during the study period.

brucellosis Risk factors

Evaluation of subclinical and chronic brucellosis, relapse, complications, and drug resistance in the patients with brucellosis

cohort study

  • name
  • dr. Fariba Keramat
  • dr. Saeed Bashirian
  • dr, Manoochehr karami
  • dr.Abbas Moghimbeigi
  • dr.Mohammad Yousef Alikhani
  • dr. Saeed Khakizade
  • dr. Maryam Adabi
  • dr. Mehran Rajabi
  • dr. Mehdi Dinari
  • Zahra Shivapour
  • position
  • Administration Manager
  • Executive team member
  • Executive team member
  • Executive team member
  • Executive team member
  • Develop executive instructions for blood sampling and quality control
  • Head of Comprehensive Research Laboratory
  • Head of Famenin Health Center
  • Head of Famenin Health Center
  • MSC in epidemiology
  • name
  • Professor of Infectious Diseases
  • PhD in Health Education and Promotion
  • PhD in epidemiology
  • PhD in Biostatistics
  • PhD in microbioligy
  • Professional Doctor of Laboratory Sciences
  • PhD in microbioligy
  • General
  • General
  • supervisor, development instructions, quality control

Rationale and design paper

Keramat F, Karami M, Alikhani MY, Bashirian S, Moghimbeigi A, Adabi M. Cohort profile: Famenin Brucellosis Cohort Study. J Res Health Sci. 2019 Aug 3;19(3):e00453. PMID: 31586374; PMCID: PMC7183558.https://pubmed.ncbi.nlm.nih.gov/31586374/

 HBCS Questionnaires

1- Phaz1 1 questionnaireQuestionaire A- PHAZE 1 HBCS

2- Phaze 2 questionnare questionnaire B PHAZE 2 HBCS